METTL3 and metabolic dysfunction-associated steatotic liver disease: In free fatty acid (FFA)-treated hepatocytes and NAFLD, m6A modification is increased, and aberrant m6A modification has been associated with lipotoxicity-induced increases in METTL3 [126].